Dr Reddy's Laboratories Limited
Maruti, Titan: View on stocks that may be impacted by US reciprocal tariffs
The US President Donald Trump has vowed to impose reciprocal tariffs on India and other countries from April 2, 2025 onwards. Here's a technical outlook on Indian stocks that may be impacted.
Infosys, ICICI Bank: 5 largecap stock ideas to trade amid market pullback
Technical charts show that shares of Infosys, ICICI Bank, Dr. Reddy's, Eicher Motors and Shriram Finance can potentially rally up to 15% from here on as Nifty attempts a pullback towards its 100-DMA.
Dr Reddy's faces Revlimid cliff, analysts split on future growth prospects
Dr Reddy's Laboratories share price plunged 6.66 per cent at Rs 1,203.50 per share on the NSE in Friday's intraday deals after analysts remained cautious on the company's Q3 performance
Dr Reddy's Lab Q3 results: Profit up 2.5% at Rs 1,413 cr, revenue rises 16%
Dr Reddy's Lab Q3 results: Shares of Dr Reddy's closed at Rs 1,289.35 on Thursday ahead of its results
Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'
Stocks to Watch, Jan 8, 2025: Tata Steel, Sobha, M&M, REC, SBI, RVNL, CESC
Stocks to Watch, Jan 8, 2025: From Tata Steel to Dr. Reddy's Labs, here is a list of stocks that will remain in focus today
Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market
The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'
Kazakhstan authority imposes penalty of Rs 28.7 lakh on Dr Reddy's unit
Dr Reddy's Laboratories on Thursday said Kazakhstan revenue authority has levied a penalty of Rs 28.7 lakh on its subsidiary. The Department of State Revenue, Bostandyk district of Almaty, Kazakhstan has imposed the penalty on Dr Reddy's Laboratories Kazakhstan LLP towards disallowance of claim of certain expenses by the tax authorities for the calendar year 2021, the drug firm said in a regulatory filing. The order levies a penalty of KZT 17,597,212 (Rs 2.87 million), it added. "Based on our evaluation, there is no material impact on the financials, operations, or other activities of the company," the Hyderabad-based drug firm said.
Dr. Reddy's up 2% on launching Toripalimab to treat nasopharyngeal cancer
In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for Toripalimab
Stocks to watch, Nov 21: Adani Group stocks, Cipla, UPL, BoB, Tata Tech
Here is a list of stocks that will be in focus from Adani Group stocks to Tata Power
USFDA issues seven observations to Dr Reddy's Hyderabad manufacturing plant
Dr Reddy's Laboratories Ltd on Tuesday said the US health regulator has issued a Form 483 with seven observations to its active pharmaceutical ingredient manufacturing facility in Bollaram, Hyderabad. "The US Food & Drug Administration (USFDA) today completed a GMP inspection at our API manufacturing facility (CTO-2) in Bollaram, Hyderabad," Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing. The inspection was conducted from November 13-19, 2024, it added. "We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline," the company said. As per US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Dr Reddy's earnings future uncertain beyond FY27, say analysts; stock up 3%
Indian pharmaceutical major, Dr Reddy's Laboratories share surged 3.1 per cent at Rs 1,312 a piece on the BSE in Wednesday's intraday deals
Dr Reddy's recalls over 330k bottles of generic drug in US: USFDA
Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of a medication used to treat high calcium levels in the blood and hyperparathyroidism in the US market due to manufacturing issues. According to the latest Enforcement Report by the US Food and Drug Administration, Dr Reddy's is recalling the 3,31,590 bottles of Cinacalcet tablets in multiple strengths in the American market due to CGMP (current good manufacturing practice) deviations. The recall is due to the "presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit", it added. New Jersey-based Dr Reddy's Laboratories, Inc., a unit of Hyderabad-based drug major, is recalling 2,85,126 bottles of Cinacalcet tablets in 30 mg strength. Besides, the drug maker is recalling 35,880 and 10,584 bottles of 60 mg and 90 mg strengths, respectively, USFDA said. The affected lot has been produced in India, it added. US-based Dr Reddy's Laboratories, Inc. initiated the Class II nationwide (US) recall on October 9
Buy or Sell? TCS, Maruti, HUL among 7 Nifty stocks trading in oversold zone
These 7 Nifty 50 stocks are seen trading with an RSI below 30; stocks trading in oversold zone need not necessarily bounce back immediately. Here are the key levels to watch out for.
Dr Reddy's, Hetero sign voluntary licenses with Gilead for HIV drug
Gilead Sciences first launched lenacapavir under the brand name Sunlenca in the United States and European markets in 2022. It is a first-in-class HIV-1 capsid inhibitor
UBS fears slowdown in India, US pharma markets; gives 'Sell' on 4 stocks
As per UBS, the Indian pharma market is slowing down due to a sharp increase in unbranded generics
Congress vs Sebi chief Buch: Trading strategies in M&M, Pidilite, Wockhardt
After ICICI and Wockhardt; M&M, Dr.Reddy's and Pidilite are the latest company names to be dragged in the Congress versus Sebi chief controversy. Here's a technical outlook on these stocks.
Dr Reddy's declines 3% after China's regulator bans import of ADHD drug
Atomoxetine is used for treating attention deficit hyperactivity disorder (ADHD) in adults and children over six years.
Dr Reddy's Labs shares drop after US FDA gives VIA tag to Vizag facilities
Shares of Dr Reddy's Laboratories slipped up to 2 per cent at Rs 6,875.05 per share on the BSE in Monday's intraday trade
Dr Reddy's Laboratories Q1 result: Net profit dips 0.90%, revenue up 13.88%
DRL's growth was primarily driven by the robust performance of the global generics business, particularly in North America and India
